Connection Study News Today

“IBT announced earlier today that the Data Monitoring Committee (DMC) has performed the planned safety analysis of the study data of 1,403 babies. We have now also received results from the pre-planned futility analysis. It is therefore with great...

Message from the CEO The speed of recruitment of preterm infants into our large phase 3 study significantly increased in the final three months of...

Highlights Competitive EPC tenders received from a suite of highly experienced engineering firms. Boab to proceed to a competitive tendering ...

Message from the CEO IBT's vision is to become an internationally leading company in the development of pharmaceuticals in the areas of premature infants, gastrointestinal diseases and probiotics. We

Press release February 4, 2022 Message from the CEO IBT's ongoing pivotal phase lll clinical trial aims to generate data to improve survival possibilities of premature infants. This is accomplished

Investegate announcements from Infant Bacterial Therapeutics, Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2021

Investegate announcements from Infant Bacterial Therapeutics, The Connection Study continues after pre-scheduled Data Monitoring Committee (DMC) review

Investegate announcements from Infant Bacterial Therapeutics, A Blinded Evaluation of the Connection Study – Sustained Feeding Tolerance (SFT) Correlates to Clinical Outcomes

A blinded evaluation of IBT's Connection Study will be presented by Professor Josef Neu, University of Florida, at the 2021 Hot Topics in Neonatology on December 6, 2021. The evaluation reveals that even

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 - March 31, 2021 Message from the CEO IBT is conducting a phase III-study ("The Connection Study") which is the last phase of the clinical development program with the pharmaceutical candidate IBP-9414 containing Lactobacillus reuteri as active substance. The active substance is a human bacterial strain found naturally in breast milk. The objective of the study is to show that the active substance can prevent necro...